CoChat

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery

Open access
Muratori, Fabrizio, Vignati, F., Di Sacco, G., Gavazzi, L., Pellegrino, D., Del Prete, M. · 2022 · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Purpose: Bariatric surgery, as Roux-en-Y gastric bypass (RYGB), laparoscopic gastric banding (LGB), and laparoscopic sleeve gastrectomy (LSG), is considered the gold standard treatment to achieve long-term weight loss in severe obesity. In patients who fail to maintain the achieved weight, pharmacological treatment may be required. Here, we reported our real-life experience on the efficacy of liraglutide therapy in 62 patients who regained weight after bariatric surgery. Methods: We retrospectively evaluated 62 (60 F-2 M; mean age: 43.6 ± 9.9 years) patients received liraglutide for weight loss after bariatric surgery (17 RYGB, 22 LGB, and 23 LSG). Body mass index (BMI) before and after surgery was, respectively, of 45.4 ± 5.5 kg/m 2 and 29.5 ± 4.9 kg/m 2. Patients were followed up from 2016 until 2021. Liraglutide was administered after weight regain once-daily subcutaneously at starting dose of 0.6 mg and with weekly increases up to 3.0 mg. Treatments were administered when a weight regain of 10–15% occurred after reaching a minimum weight loss from bariatric surgery or if weight loss after bariatric surgery was unsatisfactory. Results: After a mean of 70.7 ± 43.7 months from any bariatric surgery, all patients started liraglutide therapy. At this time, mean BMI was 34.2 ± 4.8 kg/m 2 (mean increased BMI: 4.7 ± 2.8 kg/m 2). After a mean of 10.5 ± 4.4 months from the beginning of liraglutide, 9 patients achieved normal weight (BMI 24.1 ± 0.9 kg/m 2), and 28 were overweight (BMI 26.9 ± 1.6 kg/m 2). Twenty patients achieved grade I (BMI 32.1 ± 1.5 kg/m 2), 5 grade II (BMI 37.3 ± 2.0 kg/m 2) obesity, and none had grade III obesity (mean BMI change: − 5.1 ± 2.5 kg/m 2). The treatment was well tolerated, and no serious adverse events were recorded. Conclusion: These data confirm the efficacy and safety of liraglutide in patients who experienced weight regain after bariatric surgery. Considering the long-term follow-up, patients should be followed up regularly and the pharmacological treatment should be adapted to the weight fluctuations observed during the clinical history. Level of evidence: V. Opinions of authorities, based on descriptive studies, narrative reviews, clinical experience, or reports of expert committees.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40519-022-01403-9

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Body mass index (BMI) changes in patients treated with liraglutide according to the obesity grade. Boxes represent the interquartile range, and whiskers represent the interdecile range
Fig. 1 Body mass index (BMI) changes in patients treated with liraglutide according to the obesity grade. Boxes represent the interquartile range, and whiskers represent the interdecile rangeCC BY · PubMed Central
Fig. 2 Comparison of mean body mass index (BMI) variations after liraglutide therapy in patients treated with liraglutide according to the type of bariatric surgery. Boxes represent the interquartile range, and whiskers represent the interdecile range
Fig. 2 Comparison of mean body mass index (BMI) variations after liraglutide therapy in patients treated with liraglutide according to the type of bariatric surgery. Boxes represent the interquartile range, and whiskers represent the interdecile rangeCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. Muratori FV, Di Sacco G (2002) Efficacy of sibutramine in subjects who regained weight after bariatric surgery. Int J Obes Related Metab Disord 26(Supplement 1):S150
  2. Muratori F, Di Sacco G, Pellegrino D, Vignati F (2018) Effectiveness of liraglutide 30 mg treatment of obesity in weight regain after bariatric surgery. Obesity facts. Eur J Obes 11(supplement 1):280

Cited by

See all 51

Metadata

Authors
Muratori, F., Vignati, F., Di Sacco, G., Gavazzi, L., Pellegrino, D., & Del Prete, M.
Affiliations
Azienda Socio Sanitaria Territoriale Lariana (IT)
Corresponding author
Muratori, Fabrizio
Venue
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
Published
2022-06-28
Volume
27
Issue
7
Pages
2775-2781
ISSN
  • 1124-4909 (ISSN-L)
  • 1590-1262
OpenAlex
W4283702092
Cited by
49
References
24
Citations by year
2026: 7 · 2025: 12 · 2024: 19 · 2023: 9 · 2022: 2
FWCI
10.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Body Contouring and Surgery
Keywords
liraglutide, obesity, Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, laparoscopic adjustable gastric banding, weight loss, GLP-1 receptor agonists, pharmacotherapy, treatment efficacy, tolerability, adverse events, body mass index, morbid obesity, weight regain prevention, real-world experience
MeSH terms
Liraglutide, Adult, Gastrectomy, Humans, Middle Aged, Obesity, Obesity, Morbid, Laparoscopy, Retrospective Studies, Gastric Bypass, Weight Gain, Weight Loss, Treatment Outcome, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. https://app.cochat.ai/papers/10.1007/s40519-022-01403-9
The paper
Muratori, F., Vignati, F., Di Sacco, G., Gavazzi, L., Pellegrino, D., & Del Prete, M. (2022). Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. https://doi.org/10.1007/s40519-022-01403-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.